2019 Future of Mild Cognitive Impairment (MCI) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 65 pages | ID: 274C794BF10EN
VPAResearch

Abstracts

The global demand for Mild Cognitive Impairment (MCI) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Mild Cognitive Impairment (MCI) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Mild Cognitive Impairment (MCI) pipeline companies from advancing their products into Phase 3 or Phase 4.

Mild Cognitive Impairment (MCI) Report Description-

The 2019 pipeline study on Mild Cognitive Impairment (MCI) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Mild Cognitive Impairment (MCI) pipeline compounds.

The Mild Cognitive Impairment (MCI) pipeline guide presents information on all active drugs currently being developed for Mild Cognitive Impairment (MCI). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Mild Cognitive Impairment (MCI) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Mild Cognitive Impairment (MCI) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Mild Cognitive Impairment (MCI) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Mild Cognitive Impairment (MCI) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Mild Cognitive Impairment (MCI) pipeline report includes-

• An overview of Mild Cognitive Impairment (MCI) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Mild Cognitive Impairment (MCI) pipeline
• Company wise list of Mild Cognitive Impairment (MCI) pipeline
• Mechanism of Action wise Mild Cognitive Impairment (MCI) pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Mild Cognitive Impairment (MCI) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Mild Cognitive Impairment (MCI) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Mild Cognitive Impairment (MCI) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Mild Cognitive Impairment (MCI) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Mild Cognitive Impairment (MCI) pipeline, H1- 2019
3.5 Mechanism of Action wise Mild Cognitive Impairment (MCI) Pipeline Candidates

4 ABBVIE INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Mild Cognitive Impairment (MCI) Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 AGENEBIO INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

5.1 AgeneBio Inc Business Profile
5.2 AgeneBio Inc Mild Cognitive Impairment (MCI) Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 AVRAHAM PHARMACEUTICALS LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

6.1 Avraham Pharmaceuticals Ltd Business Profile
6.2 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment (MCI) Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 BIOGEN INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

7.1 Biogen Inc Business Profile
7.2 Biogen Inc Mild Cognitive Impairment (MCI) Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 CERESPIR INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

8.1 CereSpir Inc Business Profile
8.2 CereSpir Inc Mild Cognitive Impairment (MCI) Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 EISAI CO LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

9.1 Eisai Co Ltd Business Profile
9.2 Eisai Co Ltd Mild Cognitive Impairment (MCI) Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 ELI LILLY AND CO MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

10.1 Eli Lilly and Co Business Profile
10.2 Eli Lilly and Co Mild Cognitive Impairment (MCI) Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 INTELGENX CORP MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

11.1 IntelGenx Corp Business Profile
11.2 IntelGenx Corp Mild Cognitive Impairment (MCI) Drug Details
11.3 Drug Snapshot
  11.3.1 Originator
  11.3.2 Collaborator/Co-Developer
  11.3.3 Route of Administration
  11.3.4 Orphan Drug/Fast Track/Special Designation
  11.3.5 Geography
  11.3.6 Type of Molecular Entity
  11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 NEURON BIOPHARMA SA MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

12.1 Neuron Biopharma SA Business Profile
12.2 Neuron Biopharma SA Mild Cognitive Impairment (MCI) Drug Details
12.3 Drug Snapshot
  12.3.1 Originator
  12.3.2 Collaborator/Co-Developer
  12.3.3 Route of Administration
  12.3.4 Orphan Drug/Fast Track/Special Designation
  12.3.5 Geography
  12.3.6 Type of Molecular Entity
  12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 OCTAPHARMA AG MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

13.1 Octapharma AG Business Profile
13.2 Octapharma AG Mild Cognitive Impairment (MCI) Drug Details
13.3 Drug Snapshot
  13.3.1 Originator
  13.3.2 Collaborator/Co-Developer
  13.3.3 Route of Administration
  13.3.4 Orphan Drug/Fast Track/Special Designation
  13.3.5 Geography
  13.3.6 Type of Molecular Entity
  13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 PARTNER THERAPEUTICS INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

14.1 Partner Therapeutics Inc Business Profile
14.2 Partner Therapeutics Inc Mild Cognitive Impairment (MCI) Drug Details
14.3 Drug Snapshot
  14.3.1 Originator
  14.3.2 Collaborator/Co-Developer
  14.3.3 Route of Administration
  14.3.4 Orphan Drug/Fast Track/Special Designation
  14.3.5 Geography
  14.3.6 Type of Molecular Entity
  14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 PFIZER INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

15.1 Pfizer Inc Business Profile
15.2 Pfizer Inc Mild Cognitive Impairment (MCI) Drug Details
15.3 Drug Snapshot
  15.3.1 Originator
  15.3.2 Collaborator/Co-Developer
  15.3.3 Route of Administration
  15.3.4 Orphan Drug/Fast Track/Special Designation
  15.3.5 Geography
  15.3.6 Type of Molecular Entity
  15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 PROTEKT THERAPEUTICS LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

16.1 Protekt Therapeutics Ltd Business Profile
16.2 Protekt Therapeutics Ltd Mild Cognitive Impairment (MCI) Drug Details
16.3 Drug Snapshot
  16.3.1 Originator
  16.3.2 Collaborator/Co-Developer
  16.3.3 Route of Administration
  16.3.4 Orphan Drug/Fast Track/Special Designation
  16.3.5 Geography
  16.3.6 Type of Molecular Entity
  16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 SBI PHARMACEUTICALS CO LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

17.1 SBI Pharmaceuticals Co Ltd Business Profile
17.2 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment (MCI) Drug Details
17.3 Drug Snapshot
  17.3.1 Originator
  17.3.2 Collaborator/Co-Developer
  17.3.3 Route of Administration
  17.3.4 Orphan Drug/Fast Track/Special Designation
  17.3.5 Geography
  17.3.6 Type of Molecular Entity
  17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 THERAPIX BIOSCIENCES LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

18.1 Therapix Biosciences Ltd Business Profile
18.2 Therapix Biosciences Ltd Mild Cognitive Impairment (MCI) Drug Details
18.3 Drug Snapshot
  18.3.1 Originator
  18.3.2 Collaborator/Co-Developer
  18.3.3 Route of Administration
  18.3.4 Orphan Drug/Fast Track/Special Designation
  18.3.5 Geography
  18.3.6 Type of Molecular Entity
  18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19. LATEST MILD COGNITIVE IMPAIRMENT (MCI) DRUG PIPELINE DEVELOPMENTS, 2019

20. APPENDIX

20.1 About Us
20.2 Sources and Methodology
20.3 Contact Information